DISEASE CHARACTERISTICS:

• Histologically confirmed malignancy of 1 of the following types:

  • Solid tumor

  • Hodgkin's or non-Hodgkin's lymphoma

    • Bone marrow assessment must have been performed within the past 6 weeks
• Metastatic or unresectable disease
• Standard curative or palliative therapy does not exist or is no longer effective
• No known symptomatic or untreated brain metastases

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2 OR
• Karnofsky 60-100%

Life expectancy

• More than 12 weeks

Hematopoietic

• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3

Hepatic

• Bilirubin normal
• AST and ALT ≤ 2.5 times upper limit of normal (ULN)

Renal

• Creatinine ≤ 1.5 times ULN OR
• Creatinine clearance ≥ 60 mL/min

Cardiovascular

• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other uncontrolled illness
• No active or ongoing infection
• No psychiatric illness or social situation that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy

• More than 4 weeks since prior immunotherapy
• No concurrent colony-stimulating factors (CSFs) during the first course of study drug administration
• No concurrent prophylactic CSFs
• No concurrent anticancer biologic therapy

Chemotherapy

• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

Endocrine therapy

• Male patients receiving treatment for prostate cancer must continue luteinizing hormone-releasing hormone agonist therapy to maintain castrate levels of testosterone
• Concurrent hormone replacement therapy allowed
• Concurrent megestrol for supportive care allowed provided started ≥ 1 month before study entry
• No concurrent dexamethasone
• No concurrent anticancer hormonal therapy

Radiotherapy

• More than 4 weeks since prior radiotherapy
• No prior radiotherapy to ≥ 50% of total marrow volume
• No concurrent anticancer radiotherapy

Surgery

• Not specified

Other

• Recovered from all prior therapy
• More than 4 weeks since prior epidermal growth factor receptor inhibitors
• More than 7 days since prior and no concurrent grapefruit juice

• More than 14 days since prior and no concurrent moderate to significant inhibitors or inducers of CYP3A4, including the following:

  • Clarithromycin
  • Erythromycin
  • Troleandomycin
  • Itraconazole
  • Ketoconazole
  • Fluconazole (dose > 200 mg/day)
  • Voriconazole
  • Nefazodone
  • Fluvoxamine
  • Verapamil
  • Diltiazem
  • Bitter orange
  • Phenytoin
  • Carbamazepine
  • Phenobarbital
  • Rifampin
  • Rifabutin
  • Rifapentine
  • Hypericum perforatum (St. John's wort)
  • Modafinil
  • Oxcarbazepine
• No other investigational agents within 28 days before, during, and for at least 14 days after study treatment
• More than 6 months since prior and no concurrent amiodarone
• Concurrent bisphosphonates for supportive care allowed provided started ≥ 1 month before study entry
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent cytotoxic anticancer therapy
• No other concurrent anticancer therapy

• No concurrent use of any of the following:

  • Ajmaline
  • Cimetidine
  • Clotrimazole
  • Cyclosporine
  • Fluoxetine
  • Indinavir
  • Nelfinavir
  • Paroxetine
  • Quinidine
  • Ritonavir
  • Saquinavir
  • Sertraline